Laura González-Saiz1, Alejandro Santos-Lozano1,2, Carmen Fiuza-Luces1, Paz Sanz-Ayán3,4, Carlos A Quezada-Loaiza5, Ana Ruiz-Casado6, Lidia B Alejo1,7, Angela Flox-Camacho3, María Morán1,8, Alejandro Lucia1,7,9, Pilar Escribano-Subías3,10. 1. Research Institute of Hospital 12 de Octubre ("i+12"), Madrid, Spain. 2. i+HeALTH, European University Miguel de Cervantes, Valladolid, Spain. 3. Pulmonary Hypertension Unit, Hospital Universitario 12 de Octubre, Madrid, Spain. 4. Department of Rehabilitation, Hospital Universitario 12 de Octubre, Madrid, Spain. 5. Unidad Multidisciplinar de Hipertension Pulmonar, Servicio de Neumologia, Hospital Universitario Ramon y Cajal. Instituto Ramon y Cajal de Investigacion Sanitaria, Madrid, Spain. 6. Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain. 7. European University, Madrid, Spain. 8. Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, Spain. 9. Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain. 10. CIBER de Enfermedades Cardiovasculares, Instituto de Salud Carlos III, Madrid, Spain.
Abstract
BACKGROUND: Pulmonary hypertension (PH) leads to exercise capacity impairment, but limited data are available on the objective evaluation of physical activity (PA) levels in these patients. METHODS: We assessed PA levels using triaxial accelerometry in Spanish PH patients (n=75, 48±14 years, 65% female) and gender/age matched controls (n=107), and examined potential associations of meeting minimum international recommendations [moderate-vigorous PA (MVPA) ≥150 min/week] with survival predictors. RESULTS: With the exception of vigorous PA (with very low values in both groups), all accelerometry data showed significant differences between patients and controls, with lower PA levels and proportion of individuals meeting minimum PA guidelines, but higher inactivity time, in the former. Notably, the odds ratio (OR) of having a "low-risk" value of 6-minute walking distance (≥464 m) or ventilatory equivalent for carbon dioxide (≤39) was higher in patients following MVPA guidelines than in their less active peers [OR =4.3, 95% confidence interval (CI), 1.6-11.6, P=0.005, and OR =4.5, 95% CI, 0.9-21.1, P=0.054]. CONCLUSIONS: Daily PA is reduced in patients with PH, often to a level that may decrease their odds of survival. Efforts should be made to promote the implementation of healthy PA habits in this patient population.
BACKGROUND: Pulmonary hypertension (PH) leads to exercise capacity impairment, but limited data are available on the objective evaluation of physical activity (PA) levels in these patients. METHODS: We assessed PA levels using triaxial accelerometry in Spanish PH patients (n=75, 48±14 years, 65% female) and gender/age matched controls (n=107), and examined potential associations of meeting minimum international recommendations [moderate-vigorous PA (MVPA) ≥150 min/week] with survival predictors. RESULTS: With the exception of vigorous PA (with very low values in both groups), all accelerometry data showed significant differences between patients and controls, with lower PA levels and proportion of individuals meeting minimum PA guidelines, but higher inactivity time, in the former. Notably, the odds ratio (OR) of having a "low-risk" value of 6-minute walking distance (≥464 m) or ventilatory equivalent for carbon dioxide (≤39) was higher in patients following MVPA guidelines than in their less active peers [OR =4.3, 95% confidence interval (CI), 1.6-11.6, P=0.005, and OR =4.5, 95% CI, 0.9-21.1, P=0.054]. CONCLUSIONS: Daily PA is reduced in patients with PH, often to a level that may decrease their odds of survival. Efforts should be made to promote the implementation of healthy PA habits in this patient population.
Authors: Ana Ruiz-Casado; Ana Soria Verdugo; María J Ortega Solano; Itziar Pagola Aldazabal; Carmen Fiuza-Luces; Lidia Brea Alejo; Julio R Padilla del Hierro; Isabel Palomo; Oscar Aguado-Arroyo; Nuria Garatachea; Héctor Cebolla; Alejandro Lucia Journal: Oncol Nurs Forum Date: 2014-01-01 Impact factor: 2.172
Authors: G H Guyatt; S O Pugsley; M J Sullivan; P J Thompson; L Berman; N L Jones; E L Fallen; D W Taylor Journal: Thorax Date: 1984-11 Impact factor: 9.139
Authors: Derliz Mereles; Nicola Ehlken; Sandra Kreuscher; Stefanie Ghofrani; Marius M Hoeper; Michael Halank; F Joachim Meyer; Gabriele Karger; Jan Buss; Jana Juenger; Nicole Holzapfel; Christian Opitz; Jörg Winkler; Felix F J Herth; Heinrike Wilkens; Hugo A Katus; Horst Olschewski; Ekkehard Grünig Journal: Circulation Date: 2006-09-18 Impact factor: 29.690
Authors: Lea Ann Matura; Haochang Shou; Jason S Fritz; K Akaya Smith; Anjali Vaidya; Diane Pinder; Christine Archer-Chicko; Danielle Dubow; Harold I Palevsky; Marilyn S Sommers; Steven M Kawut Journal: Chest Date: 2016-02-15 Impact factor: 9.410
Authors: Ali A Weinstein; Lisa M K Chin; Randall E Keyser; Michelle Kennedy; Steven D Nathan; Joshua G Woolstenhulme; Gerilynn Connors; Leighton Chan Journal: Respir Med Date: 2013-03-07 Impact factor: 3.415
Authors: Shelley Shapiro; Robert C Bourge; Patti Pozella; David F Harris; Erick H Borg; Andrew C Nelsen Journal: Pulm Circ Date: 2020-04-22 Impact factor: 3.017
Authors: Karen S W Chia; Peter K K Wong; Senen Gonzalez; Eugene Kotlyar; Steven G Faux; Christine T Shiner Journal: Pulm Circ Date: 2020-05-14 Impact factor: 3.017